Open AccessInhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
Author(s) -
Nagoya Takuro,
Kamimura Kenya,
Goto Ryo,
ShinagawaKobayashi Yoko,
Niwa Yusuke,
Kimura Atsushi,
Sakai Norihiro,
Ko Masayoshi,
Nishina Hiroshi,
Terai Shuji
Publication year - 2019
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12734
Subject(s) - nonalcoholic steatohepatitis , cotransporter , kidney disease , kidney , medicine , renal injury , urology , sodium , steatohepatitis , disease , endocrinology , nonalcoholic fatty liver disease , chemistry , fatty liver , organic chemistry
The effect of sodium‐glucose cotransporter 2 inhibitor (SGLT2I) on nonalcoholic steatohepatitis (NASH) has been reported, but there are few studies on its effect on NASH‐related renal injury. In this study, we examined the effect of SGLT2I using a novel medaka fish model of NASH‐related kidney disease, which was developed by feeding the d‐rR/Tokyo strain a high‐fat diet. SGLT2I was administered by dissolving it in water of the feeding tank. SGLT2I ameliorates macrophage accumulation and oxidative stress and maintained mitochondrial function in the kidney. The results demonstrate the effect of SGLT2I on NASH‐related renal injury and the usefulness of this novel animal model for research into NASH‐related complications.